Ezivac%2525252525252525252525252525252525252525252525252525252520enema

# Ezivac enema ## Overview Ezivac enema is a hyperosmotic laxative solution containing sodium phosphates. It works by drawing water into the bowel, softening stool and stimulating bowel evacuation. ## Primary Indications * Relief of occasional constipation. * Bowel preparation prior to diagnostic procedures or surgery. ## Adult Dosing * **Constipation:** Typically, a single dose of 1 unit (containing 4.4 oz or 130 mL solution) administered rectally. The dose may be repeated once in 24 hours if necessary, but not more than once in 24 hours. * **Bowel Preparation:** Follow specific institutional or physician's protocol. Doses may vary. ## Pediatric Dosing * **Children aged 2-12 years:** Use with caution. A dose of 2.5 oz (75 mL) is generally recommended. Not for use in children under 2 years of age without physician guidance. * **Children under 2 years:** Safety and efficacy not established. Consult physician. ## Dose Adjustments No specific dose adjustments are typically required based on renal or hepatic impairment, but use with caution in patients with these conditions due to potential for electrolyte disturbances. ## Contraindications * Congenital or acquired megacolon. * Intestinal obstruction or stenosis. * Appendicitis or symptoms of appendicitis. * Rectal bleeding of unknown origin. * Congenital intestinal atresia. * Heart failure or significant renal impairment. * Patients on sodium-restricted diets. * Children under 2 years of age (without medical supervision). ## Adverse Effects Common: Abdominal cramps, nausea, vomiting, diarrhea, bloating, rectal irritation. Serious: Electrolyte imbalances (hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia), dehydration, renal toxicity, cardiac arrhythmias, central nervous system depression, seizures, anaphylaxis. ## Key Drug Interactions * **Diuretics:** Increased risk of electrolyte imbalance. * **ACE inhibitors, Angiotensin II Receptor Blockers (ARBs), Potassium-sparing diuretics:** Increased risk of hyperkalemia. * **Drugs Affected by Electrolyte Shifts (e.g., Digoxin):** Increased sensitivity to these drugs due to electrolyte disturbances. ## Monitoring * Monitor for signs and symptoms of electrolyte imbalance (e.g., confusion, muscle weakness, irregular heartbeat). * Assess for adequate hydration. * Monitor bowel movements for frequency and consistency. * In patients with renal impairment, monitor renal function. ## Clinical Pearls * Administer slowly and retain for the duration recommended by the manufacturer (typically 5-30 minutes) or physician. * Avoid use in children under 2 years of age. * Do not use if bowel movements have not occurred for 3 days or if experiencing nausea, vomiting, or abdominal pain without a physician's direction. * Warn patients about the potential for explosive diarrhea and to use in a bathroom facility. * Use with caution in the elderly and those with compromised renal function due to the risk of electrolyte disturbances. *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always verify current prescribing information from the manufacturer's package insert or a reputable drug database.